Figure 1From: Impact of sphingomyelin levels on coronary heart disease and left ventricular systolic function in humansMedian SM levels between CHD and non-CHD patients, and between patients with LV systolic dysfunction (LVEF<50%) and controls (LVEF≥50%). Panel A, CHD vs Non-CHD; Panel B, LVEF<50% vs LVEF≥50%.Back to article page